Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|February 20, 2018
The Gastroenterology Group, PC, Announces Expansion into Clinical Research
Advertisement
Reston, Va., Feb. 20, 2018 (Business Wire)-The Gastroenterology Group, PC, a gastroenterology practice based in Reston, Va., announces its expansion into clinical research by partnering with Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients.
The Gastroenterology Group is now offering clinical trials, allowing it to introduce the latest advances in research to its patients. As a result, the clinic’s patients have access - in the convenience of the clinic’s office - to treatments they might not otherwise have. The Gastroenterology Group recognizes the importance of conducting clinical research for its patients and community and doing its part to advance health care around the world.
“As a practice on the forefront of medicine, we are pleased to be able to offer clinical trials as treatment options for our patients. This will give our patients access to novel therapies that they would otherwise not have,” said Emil E. Valle, M.D., of The Gastroenterology Group. “Expanding treatment options for conditions, such as inflammatory bowel disease, is extremely important to provide optimal care. It was Elligo’s unique approach of providing clinical trial infrastructure at no cost that made offering trials feasible. We look forward to being a part of the Elligo network.”
“Elligo is delighted to be working with The Gastroenterology Group to advance the care its physicians are offering to patients,” said John Potthoff, Ph.D., co-founder and CEO of Elligo Health Research. “We provide the personnel, processes, technology and infrastructure to make the clinical research process easier for clinics at no cost, so they can focus on taking care of patients.”
About The Gastroenterology Group, PC
At The Gastroenterology Group, we believe that each patient and doctor becomes a team for treating an individual's digestive problems. Our gastroenterologists spend most of their time listening to understand your concerns and to respond with the best treatment options for you. Our professional staff understands the importance of following up to make sure that problems are resolved and your health improves.
CONTACT:
Lea Studer
SCORR Marketing
402-366-1752
lea@scorrmarketing.com
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Where AI Governance in Clinical Development Falls Short
5